Table 2.
Outcomes reported in previous studies comparing IncrPD and stPD
| Publication details | Peritonitis | Glucose exposure | RKF | Cost | QOL | Solute clearance | Technique survival | Mortality |
|---|---|---|---|---|---|---|---|---|
| Ankawi et al.10 | IncrPD peritonitis rate for the 3 yr before the study was 0.34, 0.48, and 0.30 episodes per patient-year. Rate for year of the study was 0.27 episodes per patient-year. Peritonitis for stPD NR. | NR | Among those achieving Kt/V >1.7, residual renal creatinine clearance was significantly greater in incrPD (6.2 ± 3.4 vs. 2.7 ± 2.4 ml/min, P < 0.0001). | NR | NR | Among those achieving Kt/V > 1.7, no significant difference in peritoneal Kt/V (incrPD 1.15 ± 0.3 vs. stPD 1.62 ± 0.4, P < 0.0001). | Duration on PD was significantly less in incremental group (15 ± 14 vs. 27 ± 26 mo, P < 0.001). | NR |
| Jeloka et al.14 | Peritonitis rate incrPD 0.21 vs. stPD 0.47 episodes per patient-year (P value NR) | NR | NR | NR | NR | NR | NR | Patient survival significantly longer in the incrPD group (incrPD 42.84 ± 7 vs. stPD 25.29 ± 9.2 mo, P = 0.01) |
| Lee et al.12 | No difference in incidence rate of first peritonitis (incrPD 0.10 episodes per patient-year, 95% CI 0.08–0.13 vs. stPD 0.10, 95% CI 0.08–0.12). Recurrent events of peritonitis NR. Median time to first episode of peritonitis overall 2.3 yr (NR for incrPD vs. stPD). No difference in probability of remaining peritonitis-free (P = 0.860). |
NR | Reduced risk of anuria in incremental group (HR 0.61, 95% CI 0.43–0.88, P = 0.007) | NR | NR | NR | No difference in time to technique failure (incrPD 2.7 vs. stPD 2.9 yr, P = 0.332) | No difference in death from any cause (10.9 vs. 7.6 events per 1000 person-years, P = 0.449) |
| Sandrini et al.13 | Incidence of peritonitis was 0.09 episodes per patient-year in incrPD vs. 0.23 episodes per patient-year in stPD. No difference in probability of remaining peritonitis-free (P value NR). | NR | Residual renal function was lower in the stPD at 6 mo (incrPD 6.20 ± 2.02 vs. stPD 4.48 ± 2.96 ml/min per 1.73 m2, P < 0.001) and at the end of treatment (incrPD 4.36 ± 2.96 vs. stPD 2.03 ± 2.55 ml/min per 1.73 m2, P < 0.001) | NR | NR | No difference in twKt/V at 6 mo (incrPD 2.13 ± 0.45 vs. stPD 2.20 ± 0.43 ml/min per 1.73 m2, P = 0.527) but stPD significantly greater at end of treatment (incrPD 1.77 ± 0.50 vs. stPD 2.01 ± 0.35 ml/min per 1.73 m2, P = 0.007). | NR | No difference in patient survival by intention-to-treat (P = 0.057) or as-treated (P value NR) |
| Yan et al.11 | Nominally lower proportion of incrPD patients who experienced peritonitis (incrPD 13% vs. stPD 26%, P = 0.06). Nominally longer peritonitis-free survival in incrPD (log-rank = 3.811, P = 0.05). |
Glucose exposure significantly lower in the incrPD (incrPD 100 vs. stPD 127 g/d, P < 0.001) | No difference in GFR at follow-up (incrPD 1.6 ± 2.0 vs. stPD 1.7 ± 1.9 ml/min, P = 0.8) No difference in GFR decline rates (incrPD 0.17 ± 0.13 vs. stPD 0.20 ± 0.11 ml/min per mo, P = 0.2). No difference in urine volume at follow-up (incrPD 505 ± 522 vs. stPD 474 ± 442 ml/d, P = 0.8). No difference in anuria-free survival between groups (log-rank = 0.055, P = 0.8). |
NR | NR | Total Kt/V significantly less in incrPD (incrPD 1.95 ± 0.39 vs. stPD 2.19 ± 0.48 ml/min, P = 0.03). | No difference in technique survival (log-rank = 0.347, P = 0.6) | No difference in patient survival (log-rank = 0.978, P = 0.3) |
| Yu et al.6 | NR | NR | NR | NR | NR | NR | NR | Significantly lower mortality risk in standard group (HR 0.64, 95% CI 0.62–0.66) |
HR, hazard ratio; incrPD, incremental PD; NR, not reported; PD, peritoneal dialysis; QOL, quality of life; RKF, residual kidney function; stPD, standard PD; twKt/V, total weekly Kt/V.